PMID- 31178950
OWN - NLM
STAT- MEDLINE
DCOM- 20200127
LR  - 20220408
IS  - 1942-0994 (Electronic)
IS  - 1942-0900 (Print)
IS  - 1942-0994 (Linking)
VI  - 2019
DP  - 2019
TI  - Pretreatment Serum Uric Acid as an Efficient Predictor of Prognosis in Men with 
      Laryngeal Squamous Cell Cancer: A Retrospective Cohort Study.
PG  - 1821969
LID - 10.1155/2019/1821969 [doi]
LID - 1821969
AB  - PURPOSE: Uric acid (UA) is a major antioxidant molecule that has been 
      hypothesized to have a protective effect against cancer-induced oxidative damage. 
      The aim of the present study was to investigate whether preoperative levels of 
      serum UA are associated with the prognosis of laryngeal squamous cell cancer 
      (LSCC). METHODS: A total of 814 male LSCC patients (followed up for five years) 
      and 814 normal control subjects were enrolled from January 2007 to December 2011. 
      The rates of total mortality and cancer mortality were 23.46% and 21.36%, 
      respectively. The prevalence of overall survival (OS), disease-free survival 
      (DFS), and cancer-specific survival (CSS) was analysed using the Kaplan-Meier 
      method. Univariate and multivariate Cox regression models were evaluated to 
      identify UA as a prognostic factor. RESULTS: The serum UA and UA/Cr (creatinine) 
      ratio levels were significantly reduced (P < 0.001 for both) in the LSCC group 
      compared with the control group. The applied multivariate Cox regression model 
      analysis found that low levels of UA and the UA/Cr ratio were independent poor 
      prognostic factors for OS (UA (HR (95% CI) = 1.458 (1.095-1.942)), UA/Cr ratio 
      (HR (95% CI) = 1.337 (1.004-1.780))), DFS (UA (HR (95% CI) = 1.504 
      (1.131-2.001)), UA/Cr ratio (HR (95% CI) = 1.376 (1.030-1.839))), and CSS (UA (HR 
      (95% CI) = 1.494 (1.109-2.012)), UA/Cr ratio (HR (95% CI) = 1.420 
      (1.049-1.923))). The patients with high UA (>0.310 mmol/l) and UA/Cr ratio 
      (>3.97) experienced five more years of OS, DFS, and CSS than did patients with 
      low UA (<0.310 mmol/l) and UA/Cr ratio (<3.97) levels. CONCLUSION: High 
      preoperative UA serum levels were identified as an independent prognostic factor 
      associated with improved clinical outcomes among LSCC patients.
FAU - Hsueh, Chi-Yao
AU  - Hsueh CY
AUID- ORCID: 0000-0002-9679-7098
AD  - Department of Otolaryngology, Eye & ENT Hospital, Shanghai Medical College, Fudan 
      University, Shanghai, China.
AD  - Shanghai Key Clinical Disciplines of Otorhinolaryngology, Shanghai Medical 
      College, Fudan University, Shanghai, China.
FAU - Shao, Mingxi
AU  - Shao M
AUID- ORCID: 0000-0002-2189-458X
AD  - Department of Clinical Laboratory, Eye & ENT Hospital, Shanghai Medical College, 
      Fudan University, Shanghai, China.
FAU - Cao, Wenjun
AU  - Cao W
AUID- ORCID: 0000-0002-2355-2970
AD  - Department of Clinical Laboratory, Eye & ENT Hospital, Shanghai Medical College, 
      Fudan University, Shanghai, China.
FAU - Li, Shengjie
AU  - Li S
AUID- ORCID: 0000-0002-6443-740X
AD  - Department of Clinical Laboratory, Eye & ENT Hospital, Shanghai Medical College, 
      Fudan University, Shanghai, China.
FAU - Zhou, Liang
AU  - Zhou L
AUID- ORCID: 0000-0002-8588-2959
AD  - Department of Otolaryngology, Eye & ENT Hospital, Shanghai Medical College, Fudan 
      University, Shanghai, China.
AD  - Shanghai Key Clinical Disciplines of Otorhinolaryngology, Shanghai Medical 
      College, Fudan University, Shanghai, China.
LA  - eng
PT  - Journal Article
DEP - 20190416
PL  - United States
TA  - Oxid Med Cell Longev
JT  - Oxidative medicine and cellular longevity
JID - 101479826
RN  - 268B43MJ25 (Uric Acid)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Carcinoma, Squamous Cell/*blood/*diagnosis/pathology
MH  - Cohort Studies
MH  - Humans
MH  - Laryngeal Neoplasms/*blood/*diagnosis/pathology
MH  - Male
MH  - Middle Aged
MH  - Prognosis
MH  - Retrospective Studies
MH  - Uric Acid/*blood
PMC - PMC6501142
EDAT- 2019/06/11 06:00
MHDA- 2020/01/28 06:00
PMCR- 2019/04/16
CRDT- 2019/06/11 06:00
PHST- 2018/12/16 00:00 [received]
PHST- 2019/02/18 00:00 [revised]
PHST- 2019/03/07 00:00 [accepted]
PHST- 2019/06/11 06:00 [entrez]
PHST- 2019/06/11 06:00 [pubmed]
PHST- 2020/01/28 06:00 [medline]
PHST- 2019/04/16 00:00 [pmc-release]
AID - 10.1155/2019/1821969 [doi]
PST - epublish
SO  - Oxid Med Cell Longev. 2019 Apr 16;2019:1821969. doi: 10.1155/2019/1821969. 
      eCollection 2019.